BCYC News and Press, Bicycle Therapeutics plc From 11/02/23

2023-11-02 09:14:48 ET More on Bicycle Therapeutics Bicycle Therapeutics: Pedaling Through Uncertainty Bicycle Therapeutics gains as FDA expedites path for bladder cancer therapy Seeking Alpha’s Quant Rating on Bicycle Therapeutics Historical earnings ...

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

R&D Day on December 14 to provide clinical updates for BT8009, BT5528 and BT7480, and highlight broad capabilities of novel Bicycle ® technology Alignment with FDA on expedited development and design of Phase 2/3 registrational trial for BT8009 in metastatic bladder cancer, t...

Bicycle Therapeutics plc (BCYC) is expected to report $-1.06 for Q3 2023

2023-10-23 14:25:26 ET More on Seattle Genetics Seagen Acquisition By Pfizer: A Strategic Power Move With Potential Windfalls For Investors Seagen ticks higher as EU approves $43B sale to Pfizer Pfizer likely turned over all documents to FTC for Seagen acquistion - r...

Program intended to facilitate CMC development for selected therapies with expedited clinical development timeframes to help patients get access sooner Bicycle Therapeutics (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its pro...

EDINBURGH and CAMBRIDGE, United Kingdom, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has appointed Kevin Lee Ph.D., MBA as Independent Non-Executive Director. Based in the UK and CEO of Cambridge, UK/Cambridge, US based, Bicycle The...

2023-10-13 15:00:54 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...

2023-10-10 16:24:43 ET Summary Bicycle Therapeutics has strong collaborations and a robust cash position but faces escalating R&D costs and high short interest. Preclinical data for Pb-BCY20603 is promising, yet transitioning from rodent models to FDA approval remains a substa...

2023-10-06 15:00:00 ET More on the stock market The U.S. Government Shutdown: Not A Crisis SPY Madness: 'Magnificent Seven' Stocks Up An Average 95% YTD While The Average Stock Is Down More Shades Of 2007 Buy-rated dividend stocks for volatility and high rate...